{"filing":{"accession_number":"0001213900-26-083604","cik":"0001723069","ticker":"TLSA","company_name":"Tiziana Life Sciences Ltd","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ea0300024-6k_tiziana.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723069/000121390026083604/ea0300024-6k_tiziana.htm"},"events":[{"id":22814,"run_id":20650,"accession_number":"0001213900-26-083604","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive clinical trial results from a Phase 2 study of intranasal foralumab in Multiple System Atrophy patients, specifically quantitative PET imaging data showing reductions in brain inflammation (up to 34% SUV reduction) in the third patient to complete dosing. The disclosure is a clinical milestone announcement for the company's lead candidate, demonstrating reproducible biological activity across three patients. While not a traditional earnings release or discrete M\u0026A/governance event, this represents a material operational/clinical development that would affect a reasonable investor's assessment of the company's pipeline progress and therapeutic potential.","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22879,"accession_number":"0001213900-26-083604","item_number":"EX-99.1","item_title":"ea030002401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive clinical trial results from a Phase 2 study of intranasal foralumab in Multiple System Atrophy patients, specifically quantitative PET imaging data showing reductions in brain inflammation (up to 34% SUV reduction) in the third patient to complete dosing. The disclosure is a clinical milestone announcement for the company's lead candidate, demonstrating reproducible biological activity across three patients. While not a traditional earnings release or discrete M\u0026A/governance event, this represents a material operational/clinical development that would affect a reasonable investor's assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:31:24.394048+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22879,"accession_number":"0001213900-26-083604","item_number":"EX-99.1","item_title":"ea030002401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive clinical trial results from a Phase 2 study of intranasal foralumab in Multiple System Atrophy patients, specifically quantitative PET imaging data showing reductions in brain inflammation (up to 34% SUV reduction) in the third patient to complete dosing. The disclosure is a clinical milestone announcement for the company's lead candidate, demonstrating reproducible biological activity across three patients. While not a traditional earnings release or discrete M\u0026A/governance event, this represents a material operational/clinical development that would affect a reasonable investor's assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:31:24.394048+00:00","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-07-31"}]}